Latest California Healthline Stories
California’s Massive Medicaid Program Works for Some, but Fails Many Others
Medi-Cal serves more than one-third of the state’s population — offering a dizzying range of care to a diverse population. In the new “Faces of Medi-Cal” series, California Healthline will assess the program’s strengths and weaknesses through the lives and experiences of its enrollees.
Nearly $50,000 a Week for a Cancer Drug? A Man Worries About Bankrupting His Family
When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.
Racial Disparities in Lung Cancer Start With Research
Improving lung cancer outcomes in Black communities will take more than lowering the screening age, experts say. Disparities are present in everything from the studies that inform when people should get checked to the availability of care in rural areas.
Readers and Tweeters Decry Medical Billing Errors, Price-Gouging, and Barriers to Benefits
KHN gives readers a chance to comment on a recent batch of stories.
Despite Katie Couric’s Advice, Doctors Say Ultrasound Breast Exams May Not Be Needed
When Katie Couric announced she had breast cancer, she urged women to get a mammogram — and, if they have dense breasts, to get supplemental screening by ultrasound. But medical experts point out that ultrasound and other auxiliary screenings haven’t been proven to do more than regular mammography in reducing mortality.
$38,398 for a Single Shot of a Very Old Cancer Drug
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?
Reporter Follows Up on ‘Cancer Moonshot’ Progress and the Bias in Digital Health Records
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Genetic Tests Create Treatment Opportunities and Confusion for Breast Cancer Patients
Doctors are divided on whether blanket testing of breast cancer patients is warranted, since scientists and physicians are sometimes unsure about how to interpret the results.
La última década ha sido testigo de una rápida expansión de las pruebas genéticas. Pero, ¿cuál es su real relevancia clínica?
New Abortion Laws Jeopardize Cancer Treatment for Pregnant Patients
As abortion restrictions take effect across the South in the wake of the Supreme Court’s decision to overturn Roe v. Wade, cancer doctors are trying to decipher the laws. They’re grappling with how to discuss options with pregnant patients, who may be forced to choose whether to proceed or forgo lifesaving cancer treatments that can prove toxic for the fetus.